Cabozantinib enhances the efficacy and immune modulatory activity of anti-PD1 therapy in a syngeneic mouse model of hepatocellular carcinoma

被引：0
|
作者：
Esteban-Fabro, Roger [1 ]
Willoughby, Catherine E. [1 ]
Pique-Gili, Marta [1 ]
Peix, Judit [1 ]
Montironi, Carla [1 ]
Abril-Fornaguera, Jordi [1 ]
Torrens, Laura [1 ]
Pinyol, Roser [1 ]
Llovet, Josep M. [1 ,2 ,3 ]
机构：
[1] Liver Canc Translat Res Lab, Inst Invest Biomed August Pi i Sunyer IDIBAPS, Liver Unit, Barcelona, Spain
[2] Icahn Sch Med Mt Sinai, Mt Sinai Liver Canc Program, Tisch Canc Inst, New York, NY USA
[3] Inst Catalana Recerca & Estudis Avancats ICREA, Barcelona, Spain
来源：
JOURNAL OF HEPATOLOGY | 2020年 / 73卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
AS053
引用
收藏
页码：S40 / S40
页数：1
相关论文
共 50 条
  • [21] Obesity enhances the response to neoadjuvant anti-PD1 therapy in oral tongue squamous cell carcinoma
    Tan, Xiyan
    Li, Guoli
    Deng, Honghao
    Xiao, Guoming
    Wang, Yaqin
    Zhang, Chenzhi
    Chen, Yanfeng
    CANCER MEDICINE, 2024, 13 (12):
  • [22] Targeting STING pathway as a therapeutic strategy against ß-catenin driven immune escape and resistance to anti-PD1 therapy in hepatocellular carcinoma
    Zhang, Qingmei
    Bi, Jiacheng
    Yeung, Oscar Wai-Ho
    Ding, Tao
    Chan, Wing-Lim
    Zhu, Yueqin
    Liu, Jiang
    Ng, Kevin Tak-Pan
    Man, Kwan
    CANCER RESEARCH, 2024, 84 (06)
  • [23] COMBINATION IRREVERSIBLE ELECTROPORATION AND ANTI-PD1 THERAPY REVERSES MDSC INDUCED IMMUNE-SUPPRESSIVE MICROENVIRONMENT IN HEPATOCELLULAR CARCINOMA.
    Huo, Jihui
    Lei, Kai
    Peng, Sui
    Kuang, Ming
    Dai, Zihao
    Wang, Lina
    GASTROENTEROLOGY, 2024, 166 (05) : S1725 - S1725
  • [24] Stable liver graft post anti-PD1 therapy as a bridge to transplantation in an adolescent with hepatocellular carcinoma
    Kang, Elise
    Martinez, Mercedes
    Moisander-Joyce, Hanna
    Saenger, Yvonne M.
    Griesemer, Adam D.
    Kato, Tomoaki
    Yamashiro, Darrell J.
    Remotti, Helen
    Gartrell, Robyn D.
    PEDIATRIC TRANSPLANTATION, 2022, 26 (03)
  • [25] Over-Expression of GUSB Leads to Primary Resistance of Anti-PD1 Therapy in Hepatocellular Carcinoma
    Kong, Xiangyi
    Zheng, Zhiying
    Song, Guoxin
    Zhang, Zihao
    Liu, Hanyuan
    Kang, Junwei
    Sun, Guoqiang
    Sun, Guangshun
    Huang, Tian
    Li, Xiao
    Rong, Dawei
    Wang, Ke
    Tang, Weiwei
    Xia, Yongxiang
    FRONTIERS IN IMMUNOLOGY, 2022, 13
  • [26] Evaluation of antitumor activity of lenvatinib plus anti-PD-1 antibody combination in the hepatocellular carcinoma Hepa1-6 mouse syngeneic tumor model
    Kimura, T.
    Kato, Y.
    Ozawa, Y.
    Kodama, K.
    Ito, J.
    Ichikawa, K.
    Yamada, K.
    Hori, Y.
    Tabata, K.
    Takase, K.
    Matsui, J.
    Funahashi, Y.
    Nomoto, K.
    EUROPEAN JOURNAL OF CANCER, 2018, 103 : E126 - E127
  • [27] Immune modulatory effects of chemotherapy increase the effectiveness of anti-PD1 immunotherapy in a poorly immunogenic murine model of osteosarcoma
    Ladle, Brian H.
    Phillips, Maggie J.
    Yu, Colburn
    Gamper, Christopher J.
    JOURNAL OF IMMUNOLOGY, 2017, 198 (01):
  • [28] Targeting CD47 enhances the efficacy of anti-PD-1 immune checkpoint inhibition in syngeneic preclinical model of HCC
    Kang, Wonseok
    Yang, Sera
    Kang, Sohee
    Kim, Young
    Paik, Yong-Han
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2018, 33 : 411 - 411
  • [29] Attenuated Toxoplasma gondii enhances the antitumor efficacy of anti-PD1 antibody by altering the tumor microenvironment in a pancreatic cancer mouse model
    Said Ahmed Bahwal
    Jane J. Chen
    Lilin E
    Taofang Hao
    Jiancong Chen
    Vern B. Carruthers
    Jiaming Lai
    Xingwang Zhou
    Journal of Cancer Research and Clinical Oncology, 2022, 148 : 2743 - 2757
  • [30] Attenuated Toxoplasma gondii enhances the antitumor efficacy of anti-PD1 antibody by altering the tumor microenvironment in a pancreatic cancer mouse model
    Bahwal, Said Ahmed
    Chen, Jane J.
    E, Lilin
    Hao, Taofang
    Chen, Jiancong
    Carruthers, Vern B.
    Lai, Jiaming
    Zhou, Xingwang
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2022, 148 (10) : 2743 - 2757
12345